

Philip S Wells

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6538586/philip-s-wells-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

189
papers

17,658
citations

37
h-index

132
g-index

195
ext. papers

21,038
ext. citations

8.4
avg, IF

6.2
L-index

#	Paper	IF	Citations
189	Ruling out pulmonary embolism across different healthcare settings: A systematic review and individual patient data meta-analysis.. <i>PLoS Medicine</i> , 2022 , 19, e1003905	11.6	1
188	Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial.. <i>Thrombosis Research</i> , 2022 , 211, 85-87	8.2	1
187	Thromboprophylaxis in Patients with COVID-19. A Brief Update to the CHEST Guideline and Expert Panel Report.. <i>Chest</i> , 2022 ,	5.3	6
186	Evaluation of definitions for oral anticoagulant-associated major bleeding: A population-based cohort study.. <i>Thrombosis Research</i> , 2022 , 213, 57-64	8.2	0
185	The impact of Stress Management and Resilience Training (SMART) on academic physicians during the implementation of a new Health Information System: An exploratory randomized controlled trial.. <i>PLoS ONE</i> , 2022 , 17, e0267240	3.7	1
184	Safety and Efficiency of Diagnostic Strategies for Ruling Out Pulmonary Embolism in Clinically Relevant Patient Subgroups : A Systematic Review and Individual-Patient Data Meta-analysis.. <i>Annals of Internal Medicine</i> , 2021 ,	8	3
183	Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation : A Multicenter Prospective Cohort Study. <i>Annals of Internal Medicine</i> , 2021 ,	8	7
182	Efficacy and Safety of Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients with Cancer and Central Venous Catheter: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2021 , 138, 2139-2139	2.2	
181	Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer.. <i>Cmaj</i> , 2021 , 193, E1551-E1560	3.5	1
180	Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , 2021 , 208, 79-82	8.2	0
179	Efficacy and safety of primary thromboprophylaxis for the prevention of venous thromboembolism in patients with cancer and a central venous catheter: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2021 , 208, 58-65	8.2	2
178	Apixaban anti-Xa level monitoring in treatment of acute upper extremity deep vein thrombosis for patient on chronic hemodialysis: a case report. <i>Thrombosis Journal</i> , 2021 , 19, 23	5.6	1
177	Long-term risk of recurrent venous thromboembolism after a first contraceptive-related event: Data from REVERSE cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 1526-1532	15.4	3
176	Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , 2021 , 202, 151-154	8.2	1
175	Direct oral anticoagulant use in special populations. <i>Current Opinion in Pulmonary Medicine</i> , 2021 , 27, 311-318	3	
174	Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. <i>BMJ, The</i> , 2021 , 373, n1205	5.9	9
173	A cross-sectional study of the interrelationship between burnout, empathy and resilience in academic physicians. <i>Psychology, Health and Medicine</i> , 2021 , 1-8	2.1	1

172	Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 720-724	5.1	2
171	Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A post-hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , 2021 , 197, 13-15	8.2	2
170	Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2801-2813	15.4	1
169	Venous Thromboembolism Prophylaxis in Critically Ill Adults: A Systematic Review and Network Meta-analysis. <i>Chest</i> , 2021 ,	5.3	4
168	Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2021 , 160, e545-e608	5.3	48
167	Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2021 , 160, 2247-2259	5.3	35
166	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. <i>Annals of Internal Medicine</i> , 2021 , 174, 1420-1429	8	7
165	Life dissatisfaction in Canadians aged 40 and above with cancer and mental health disorders: A cross-sectional study using the Canadian Community Health Survey. <i>Cancer Medicine</i> , 2021 , 10, 7601-7609	4.8	1
164	Media portrayals of pulmonary embolism. <i>Thrombosis Research</i> , 2021 , 206, 52-54	8.2	
163	Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2020 , 158, 1143-1163	5.3	356
162	Risk Stratification of Pulmonary Embolism. <i>Critical Care Clinics</i> , 2020 , 36, 437-448	4.5	1
161	Venous thromboembolism prevention in intracerebral hemorrhage: A systematic review and network meta-analysis. <i>PLoS ONE</i> , 2020 , 15, e0234957	3.7	4
160	Predictive analytics by deep machine learning: A call for next-gen tools to improve health care. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 181-182	5.1	3
159	Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants. <i>American Journal of Kidney Diseases</i> , 2020 , 76, 311-320	7.4	10
158	Apixaban Anti-Xa Level Monitoring in Treatment of Provoked Acute Upper Extremity Deep Vein Thrombosis for Patient on Dialysis: A Case Report. <i>Blood</i> , 2020 , 136, 14-14	2.2	
157	D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer. <i>Oncologist</i> , 2020 , 25, 1075-1083	5.7	5
156	Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. <i>Thrombosis Research</i> , 2020 , 196, 437-443	8.2	
155	Association of Splanchnic Vein Thrombosis on Survival: 15-Year Institutional Experience With 1561 Cases. <i>Journal of the American Heart Association</i> , 2020 , 9, e016600	6	3

154	Applying rigorous eligibility criteria to studies evaluating prognostic utility of serum biomarkers in pulmonary embolism: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2020 , 195, 195-208	8.2	2
153	Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study. <i>Thrombosis Research</i> , 2020 , 191 Suppl 1, S31-S36	8.2	3
152	Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. <i>Haematologica</i> , 2020 , 105, 1436-1442	6.6	7
151	Safety of using direct oral anticoagulants in the diagnostic workup of outpatients with suspicion of acute venous thromboembolism. <i>Haematologica</i> , 2020 , 105, e307-e309	6.6	2
150	Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. <i>Haematologica</i> , 2019 , 104, e474-e477	6.6	0
149	Inferior Vena Cava Filters in the Management of Venous Thromboembolism-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 1007	27.4	
148	The value of sPESI for risk stratification in patients with pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 149-157	5.1	9
147	Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2141-2151	15.4	31
146	Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding. <i>Thrombosis Research</i> , 2019 , 182, 12-19	8.2	5
145	Safety of Primary Thromboprophylaxis Using Apixaban in Ambulatory Cancer Patients with Intracranial Metastatic Disease or Primary Brain Tumors. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1886-1887	7.8	5
144	Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism. <i>Journal of Health Economics and Outcomes Research</i> , 2019 , 6, 84-94	1.6	2
143	Cost-Utility Analysis of Apixaban Compared to Usual Care for the Primary Thromboprophylaxis of Ambulatory Cancer Patients Initiating Chemotherapy. <i>Blood</i> , 2019 , 134, 329-329	2.2	
142	Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care. <i>Journal of Health Economics and Outcomes Research</i> , 2019 , 6, 160-173	1.6	0
141	Regarding the necessity of an updated meta-analysis on the prognostic value of serum biomarkers in patients with pulmonary embolism. <i>Thrombosis Research</i> , 2019 , 176, 8-10	8.2	2
140	Extended therapy for unprovoked venous thromboembolism: when is it indicated?. <i>Blood Advances</i> , 2019 , 3, 499	7.8	0
139	Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. <i>New England Journal of Medicine</i> , 2019 , 380, 711-719	59.2	391
138	Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. <i>New England Journal of Medicine</i> , 2018 , 378, 699-707	59.2	189
137	Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results. <i>Journal of Medical Economics</i> , 2018 , 21, 587-594	2.4	1

136	Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial. <i>Thrombosis Research</i> , 2018 , 164 Suppl 1, S124-S129	8.2	21
135	Management of direct oral anticoagulant associated bleeding: Results of a multinational survey. <i>Thrombosis Research</i> , 2018 , 163, 19-21	8.2	5
134	Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. <i>Thrombosis Research</i> , 2018 , 163, 41-46	8.2	27
133	Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. <i>Thrombosis Research</i> , 2018 , 162, 7-14	8.2	18
132	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. <i>TH Open</i> , 2018 , 2, e1-e7	2.7	2
131	Sex Differences in Patients With Occult Cancer After Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018 , 24, 489-495	3.3	4
130	Diagnosis of Venous Thromboembolism: 20 Years of Progress. <i>Annals of Internal Medicine</i> , 2018 , 168, 131-140	8	24
129	DNA methylation age is associated with an altered hemostatic profile in a multiethnic meta-analysis. <i>Blood</i> , 2018 , 132, 1842-1850	2.2	11
128	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. <i>Thrombosis Research</i> , 2018 , 168, 121-129	8.2	10
127	Double Blind Randomized Control Trial of Postoperative Low Molecular Weight Heparin Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2). <i>Blood</i> , 2018 , 132, 424-424	2.2	4
126	Evaluation of Definitions for Oral Anticoagulant-Associated Major Bleeding: A Population-Based Cohort Study. <i>Blood</i> , 2018 , 132, 426-426	2.2	2
125	Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. <i>Thrombosis Research</i> , 2018 , 162, 104-109	8.2	17
124	Venous Thromboembolism: Advances in Diagnosis and Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 1583-1594	27.4	128
123	Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population. <i>Chest</i> , 2018 , 154, 1371-1378	5.3	4
122	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. <i>Blood Advances</i> , 2018 , 2, 788-796	7.8	46
121	Timing of anticoagulant re-initiation following intracerebral hemorrhage in mechanical heart valves: Survey of neurosurgeons and thrombosis experts. <i>Clinical Neurology and Neurosurgery</i> , 2017 , 154, 23-27	2	7
120	Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. <i>International Journal of Clinical Practice</i> , 2017 , 71, e12915	2.9	2
119	Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding: Characteristics, Reversal Strategies, and Outcomes From a Multicenter Observational Study. <i>Chest</i> , 2017 , 152, 81-91	5.3	53

118	External validation of a claims-based and clinical approach for predicting post-pulmonary embolism outcomes among United States veterans. <i>Internal and Emergency Medicine</i> , 2017 , 12, 613-619	3.7	3
117	Bleeding risk in patients with unprovoked venous thromboembolism: A critical appraisal of clinical prediction scores. <i>Thrombosis Research</i> , 2017 , 152, 52-60	8.2	19
116	Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease. <i>Thrombosis Research</i> , 2017 , 152, 4-6	8.2	11
115	Leveraging cell type specific regulatory regions to detect SNPs associated with tissue factor pathway inhibitor plasma levels. <i>Genetic Epidemiology</i> , 2017 , 41, 455-466	2.6	1
114	Quality of Life, Dyspnea, and Functional Exercise Capacity Following a First Episode of Pulmonary Embolism: Results of the ELOPE Cohort Study. <i>American Journal of Medicine</i> , 2017 , 130, 990.e9-990.e21	2.4	73
113	N-terminal of prohormone brain natriuretic peptide predicts functional limitation one year following pulmonary embolism: Results from the ELOPE study. <i>Thrombosis Research</i> , 2017 , 153, 47-49	8.2	4
112	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017 , 376, 1211-1222	59.2	397
111	Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism. <i>American Journal of Medicine</i> , 2017 , 130, 588-595	2.4	34
110	Functional and Exercise Limitations After a First Episode of Pulmonary Embolism: Results of the ELOPE Prospective Cohort Study. <i>Chest</i> , 2017 , 151, 1058-1068	5.3	111
109	Homocysteine levels associate with subtle changes in leukocyte DNA methylation: an epigenome-wide analysis. <i>Epigenomics</i> , 2017 , 9, 1403-1422	4.4	4
108	Blood triglyceride levels are associated with DNA methylation at the serine metabolism gene PHGDH. <i>Scientific Reports</i> , 2017 , 7, 11207	4.9	20
107	Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE. <i>Clinical Therapeutics</i> , 2017 , 39, 1396-1408	3.5	6
106	Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism. <i>Clinical Therapeutics</i> , 2017 , 39, 1426-1436.e2	3.5	2
105	Observation management of pulmonary embolism and agreement with claims-based and clinical risk stratification criteria in United States patients: a retrospective analysis. <i>BMC Pulmonary Medicine</i> , 2017 , 17, 37	3.5	1
104	Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. <i>Internal and Emergency Medicine</i> , 2017 , 12, 311-318	3.7	11
103	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. <i>Thrombosis Research</i> , 2017 , 149, 29-37	8.2	10
102	Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017 , 23, 830-837	3.3	13
101	Genetically defined elevated homocysteine levels do not result in widespread changes of DNA methylation in leukocytes. <i>PLoS ONE</i> , 2017 , 12, e0182472	3.7	8

100	Benefit of early discharge among patients with low-risk pulmonary embolism. <i>PLoS ONE</i> , 2017 , 12, e0185022	9
99	Outcomes associated with observation stays versus inpatient admissions for pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 42, 513-9	5.1 3
98	Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension. <i>Chest</i> , 2016 , 150, 1059-1068	5.3 19
97	Timing of vitamin K antagonist re-initiation following intracranial hemorrhage in mechanical heart valves: Systematic review and meta-analysis. <i>Thrombosis Research</i> , 2016 , 144, 152-7	8.2 16
96	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016 , 3, e228-36	14.6 41
95	Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2016 , 149, 315-352	5.3 3090
94	Prediction of Bleeding Risk in Patients on Extended Oral Anticoagulation for Venous Thromboembolism. <i>Blood</i> , 2016 , 128, 139-139	2.2 2
93	Post-Thrombotic Syndrome and Functional Disability in Patients with Upper Extremity Deep Vein Thrombosis: A Prospective Cohort Study. <i>Blood</i> , 2016 , 128, 417-417	2.2 2
92	Do Genetic Contributors to Warfarin Responsiveness or Common Thrombophilias Influence the Risk of Major Bleeding in Patients on Extended Duration Vitamin K Antagonist (VKA) for Venous Thromboembolic Disease?. <i>Blood</i> , 2016 , 128, 272-272	2.2
91	External Validation of a Clinical and Claims-Based Approach for Predicting 90-Day Post-Pulmonary Embolism Outcomes Among US Veterans. <i>Blood</i> , 2016 , 128, 533-533	2.2
90	Reduced Costs and Length-of-Stay Associated with Rivaroxaban As Compared to Parenteral Bridging and Warfarin in Pulmonary Embolism Patients Managed in Observation Status. <i>Blood</i> , 2016 , 128, 2337-2337	2.2
89	Risk of Venous Thromboembolism Recurrence Among Rivaroxaban Treated Patients Who Continued Versus Discontinued Therapy: Analyses Among VTE Patients. <i>Blood</i> , 2016 , 128, 144-144	2.2
88	Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohort. <i>Thrombosis Research</i> , 2016 , 143, 152-8	8.2 25
87	Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. <i>Blood</i> , 2016 , 127, 1417-25	2.2 122
86	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016 , 3, e437-45	14.6 23
85	Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxaban. <i>International Journal of Cardiology</i> , 2016 , 222, 846-849	3.3 1
84	Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding. <i>Academic Emergency Medicine</i> , 2016 , 23, 144-50	3.4 18
83	Computed Tomographic Pulmonary Angiography for Pulmonary Embolism. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 74-5	27.4 4

82	D-dimer for pulmonary embolism. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1668-9	27.4	15
81	Dalteparin for pregnant women with thrombophilia - authors' reply. <i>Lancet, The</i> , 2015 , 385, 690	40	0
80	Long-range epigenetic regulation is conferred by genetic variation located at thousands of independent loci. <i>Nature Communications</i> , 2015 , 6, 6326	17.4	90
79	Nonleg venous thrombosis in critically ill adults. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 411-2	27.4	4
78	Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study. <i>Academic Emergency Medicine</i> , 2015 , 22, 299-307	3.4	26
77	Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis. <i>Thrombosis Research</i> , 2015 , 136, 1099-102	8.2	34
76	Rivaroxaban for Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia Study. <i>Blood</i> , 2015 , 126, 3468-3468	2.2	4
75	"Post-Pulmonary Embolism Syndrome" after a First Episode of PE: Results of the E.L.O.P.E. Study. <i>Blood</i> , 2015 , 126, 650-650	2.2	5
74	Dyspnea, Quality of Life and Walking Capacity during 1 Year Follow-up after a First Episode of Pulmonary Embolism: Results of the E.L.O.P.E. Study. <i>Blood</i> , 2015 , 126, 750-750	2.2	1
73	A Prospective Cohort Study of Upper Extremity Deep Vein Thrombosis. <i>Blood</i> , 2015 , 126, 893-893	2.2	3
72	Brain Natriuretic Peptide, Troponin and D-Dimer Levels in Relation to Long-Term Functional Outcome after a First Episode of Pulmonary Embolism: Results from the E.L.O.P.E. Study. <i>Blood</i> , 2015 , 126, 649-649	2.2	
71	Treatment of venous thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 717-28	27.4	133
70	Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. <i>Lancet, The</i> , 2014 , 383, 880-8	40	322
69	Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. <i>Lancet Haematology, the</i> , 2014 , 1, e37-46	14.6	186
68	Endovascular cooling catheter related thrombosis in patients undergoing therapeutic hypothermia for out of hospital cardiac arrest. <i>Resuscitation</i> , 2014 , 85, 1354-8	4	23
67	Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. <i>Lancet, The</i> , 2014 , 384, 1673-83	40	168
66	Clinical decision rules and D-Dimer in venous thromboembolism: current controversies and future research priorities. <i>Thrombosis Research</i> , 2014 , 134, 763-8	8.2	21
65	Factors that predict thrombosis in relatives of patients with venous thromboembolism. <i>Blood</i> , 2014 , 124, 2124-30	2.2	43

64	Uitsluiten van DVT met een klinische beslisregel. <i>Huisarts En Wetenschap</i> , 2014 , 57, 626-628	0.1	
63	Therapies for venous thromboembolism--reply. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 2543-4	27.4	
62	Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy. <i>Thrombosis Journal</i> , 2014 , 12, 26	5.6	12
61	Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 1122-35	27.4	92
60	Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis. <i>Thrombosis Research</i> , 2013 , 132, 515-9	8.2	100
59	The diagnosis and treatment of venous thromboembolism. <i>Hematology American Society of Hematology Education Program</i> , 2013 , 2013, 457-63	3.1	43
58	Inflammation Markers and The Risk Of Post Thrombotic Syndrome: Results From The Bio-Sox Study. <i>Blood</i> , 2013 , 122, 36-36	2.2	3
57	Predictors Of The Post-Thrombotic Syndrome In a Large Cohort Of Patients With Proximal DVT: Secondary Analysis Of The Sox Trial. <i>Blood</i> , 2013 , 122, 460-460	2.2	2
56	Performance Of The Simplified Pesi Score In Patients With Pulmonary Embolism Treated With Rivaroxaban Or Standard Therapy. <i>Blood</i> , 2013 , 122, 1139-1139	2.2	
55	The Effectiveness Of 30-40 Mm Hg Compression Stockings To Treat Acute Leg Pain Associated With Proximal Deep Vein Thrombosis: Results From The Sox Randomized Controlled Trial. <i>Blood</i> , 2013 , 122, 1126-1126	2.2	
54	Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , 2012 , 141, e419S-e496S	5.3	2575
53	Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. <i>Circulation</i> , 2012 , 126, 448-54	16.7	142
52	Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. <i>New England Journal of Medicine</i> , 2012 , 366, 1287-97	59.2	1692
51	The diagnosis of venous thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 691-701	5.3	14
50	Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , 2012 , 141, e351S-e418S	5.3	449
49	An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. <i>Journal of Medical Economics</i> , 2011 , 14, 238-44	2.4	9
48	Comparison of the Villalta Post Thrombotic Syndrome (PTS) Score in the Ipsilateral Versus Contralateral Leg After a First Unprovoked Deep Vein Thrombosis (DVT): Results From the REVERSE Study. <i>Blood</i> , 2011 , 118, 1236-1236	2.2	
47	Frequency and Predictors of Post-Thrombotic Syndrome in Patients with a First, Unprovoked Deep Vein Thrombosis and No Prior Primary Venous Insufficiency: Results From the REVERSE Cohort Study. <i>Blood</i> , 2011 , 118, 3332-3332	2.2	

46	Oral rivaroxaban for symptomatic venous thromboembolism. <i>New England Journal of Medicine</i> , 2010 , 363, 2499-510	59.2	2240
45	Development of A Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism In Patients with Cancer-Associated Venous Thromboembolism. <i>Blood</i> , 2010 , 116, 475-475	2.2	2
44	Outcome of Saddle Pulmonary Embolism: A Nested Case-Control Study.. <i>Blood</i> , 2010 , 116, 1102-1102	2.2	
43	Validation of A Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism In Patients with Cancer-Associated Venous Thromboembolism. <i>Blood</i> , 2010 , 116, 4209-4209	2.2	
42	Patients with Cancer Who Develop a First Venous Thromboembolic Event After Surgery Are at High Risk of Venous Thromboembolism Recurrence During the Anticoagulation Period. <i>Blood</i> , 2010 , 116, 4202-4202	2.2	
41	Safety of Outpatient Treatment In Acute Pulmonary Embolism.. <i>Blood</i> , 2010 , 116, 3796-3796	2.2	
40	Outcomes of Pulmonary Embolism In Surgical Patients: A Retrospective Cohort Study. <i>Blood</i> , 2010 , 116, 3180-3180	2.2	0
39	Analysis of venous thromboprophylaxis duration and outcomes in orthopedic patients. <i>American Journal of Managed Care</i> , 2010 , 16, 857-63	2.1	13
38	Practical application of the 10-mg warfarin initiation nomogram. <i>Blood Coagulation and Fibrinolysis</i> , 2009 , 20, 403-8	1	10
37	A Systematic Review and Meta-Analysis of Proportions of Thrombosis and Bleeding in Patients Receiving Venous Thromboembolism (VTE) Prophylaxis After Orthopedic Surgery (OS). An Update.. <i>Blood</i> , 2009 , 114, 3125-3125	2.2	2
36	A Randomized, Controlled Two-Center Pilot Trial of a 6-Month Exercise Training Program to Treat the Post-Thrombotic Syndrome: The EXPO Pilot Trial.. <i>Blood</i> , 2009 , 114, 3984-3984	2.2	1
35	Pulmonary embolism: a clinician's perspective. <i>Seminars in Nuclear Medicine</i> , 2008 , 38, 404-11	5.4	13
34	Indirect Comparisons of Rivaroxaban Versus Alternative Prophylaxes for the Prevention of VTE in Patients Undergoing Total Knee Replacement.. <i>Blood</i> , 2008 , 112, 1292-1292	2.2	2
33	Alignment to ACCP Prophylaxis Guidelines and VTE Outcomes in THR and TKR Patients. <i>Blood</i> , 2008 , 112, 170-170	2.2	14
32	Trousseau's Syndrome Revisited: Should We Screen Extensively for Malignancy in Patients with Venous Thromboembolism? a Systematic Review and Meta-Analysis. <i>Blood</i> , 2008 , 112, 403-403	2.2	1
31	Cost-Effectiveness of Rivaroxaban as VTE Prophylaxis after Total Hip Replacement in Canada.. <i>Blood</i> , 2008 , 112, 1291-1291	2.2	
30	Practical Application of the 10 Mg Warfarin Initiation Nomogram. <i>Blood</i> , 2008 , 112, 4054-4054	2.2	
29	VIDAS D-Dimer in Combination with Clinical Pre-Test Probability to Rule out Pulmonary Embolism. A Systematic Review of the Management Outcome Studies.. <i>Blood</i> , 2008 , 112, 1811-1811	2.2	

28	Dose Escalation of Low Molecular Weight Heparin to Manage VTE Treatment Failure in Cancer Patients. <i>Blood</i> , 2008 , 112, 4050-4050	2.2	
27	Does this patient have deep vein thrombosis?. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 199-207	27.4	256
26	Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis. <i>American Journal of Epidemiology</i> , 2006 , 164, 101-9	3.8	70
25	The factor XIII Val34Leu polymorphism: is it protective against idiopathic venous thromboembolism?. <i>Blood Coagulation and Fibrinolysis</i> , 2006 , 17, 533-8	1	4
24	Advances in the diagnosis of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2006 , 21, 31-40	5.1	29
23	A Pilot Study of Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis of the Upper Extremity (UEDVT).. <i>Blood</i> , 2006 , 108, 878-878	2.2	1
22	The Effect of Dalteparin on Coagulation Activation during Pregnancy in Women with Thrombophilia: A Randomised Trial.. <i>Blood</i> , 2006 , 108, 874-874	2.2	
21	A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. <i>Archives of Internal Medicine</i> , 2005 , 165, 733-8		124
20	The role of qualitative D-dimer assays, clinical probability, and noninvasive imaging tests for the diagnosis of deep vein thrombosis and pulmonary embolism. <i>Seminars in Vascular Medicine</i> , 2005 , 5, 340-50		10
19	Computerized Tomographic Pulmonary Angiography Compared with Ventilation-Perfusion Lung Scanning as Initial Diagnostic Modality for Patients with Suspected Pulmonary Embolism: A Randomized Controlled Trial.. <i>Blood</i> , 2005 , 106, 1619-1619	2.2	2
18	Factor XIII Val34Leu Polymorphism and the Risk of Myocardial Infarction: A Meta-Analysis.. <i>Blood</i> , 2005 , 106, 1637-1637	2.2	
17	Ximelagatran in Major Orthopedic Surgery: A Systematic Review and Meta-Analysis of Efficacy and Safety.. <i>Blood</i> , 2005 , 106, 913-913	2.2	1
16	A Meta-Analysis to Determine the Risk of Heparin Induced Thrombocytopenia (HIT) and Isolated Thrombocytopenia in Prophylaxis Studies Comparing Unfractionated Heparin (UFH) and Low Molecular Weight Heparin (LMWH).. <i>Blood</i> , 2004 , 104, 2587-2587	2.2	4
15	Factor XIII Val34Leu Polymorphism Is Protective Against Venous Thromboembolism; a Meta-Analysis.. <i>Blood</i> , 2004 , 104, 3512-3512	2.2	
14	Overview and comparison of D-dimer assay kits for DVT and PE. <i>Clinical Advances in Hematology and Oncology</i> , 2004 , 2, 160, 178	0.6	4
13	Diagnosis of pulmonary embolism: when is imaging needed?. <i>Clinics in Chest Medicine</i> , 2003 , 24, 13-28	5.3	16
12	Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. <i>New England Journal of Medicine</i> , 2003 , 349, 1227-35	59.2	1018
11	Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. <i>New England Journal of Medicine</i> , 2003 , 349, 631-9	59.2	609

10	The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. <i>Archives of Internal Medicine</i> , 2003 , 163, 917-20		93
9	Safety and efficacy of methods for reducing perioperative allogeneic transfusion: a critical review of the literature. <i>American Journal of Therapeutics</i> , 2002 , 9, 377-88	1	37
8	Feasibility of blinding in a randomized controlled trial comparing preoperative autologous blood donation and acute normovolemic hemodilution in adult cardiac surgery. <i>Transfusion</i> , 2000 , 40, 1058-62	2.9	5
7	Surgical treatment of chronic thromboembolic pulmonary hypertension. <i>Canadian Respiratory Journal</i> , 2000 , 7, 49-57	2.1	23
6	A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. <i>New England Journal of Medicine</i> , 1999 , 340, 901-7	59.2	876
5	A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. <i>Circulation</i> , 1995 , 91, 2184-7	16.7	152
4	Application of a Novel and Rapid Whole Blood Assay for D-Dimer in Patients with Clinically Suspected Pulmonary Embolism. <i>Thrombosis and Haemostasis</i> , 1995 , 73, 035-038	7	53
3	Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin. <i>Thrombosis and Haemostasis</i> , 1994 , 71, 300-304	7	106
2	Diagnostic Management Strategies in Patients with Suspected Deep Vein Thrombosis		315-327
1	Deep Vein Thrombosis		113-122